Turkey Euro Change Too Little, Too Late For Pharma?
This article was originally published in PharmAsia News
After years of pressure by the industry and a supporting court decision, the Turkish government has finally fixed a new Euro exchange rate for the pharma industry. But the modest revision has been criticized as too little, too late and far from being a long-term solution for firms operating in the country.
You may also be interested in...
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.
The Turkish government’s drive to establish domestic manufacturing for vaccines is showing tentative signs of getting off the ground. New partnerships are forming between Turkish and international partners. However, lack of local know-how is hampering progress.